US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest

Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium

Kailera Therapeutics (KLRA):Phase III Obesity Biotech Sets Terms with Backing from Bain, QIA

IPOs and Secondary Offerings

Equity Capital Markets

Kailera Therapeutics / Equity Capital Markets

<ul>
<li>IPO Momentum Reverses: KLRA opened 62.5% above issue but has subsequently declined 58.6% from its first trade, closing October 13 at $10.77.</li>
<li>Clinical Progress Continues: Kailera has completed enrollment in its Phase 3 ribupatide obesity trial, providing an important milestone despite the stock's weakness.</li>
<li>Investor Patience Tested: Significant private-market backing has not prevented selling pressure, while potential early-investor liquidity remains an overhang.</li>
</ul>


IPO Momentum Reverses: KLRA opened 62.5% above issue but has subsequently declined 58.6% from its first trade, closing October 13 at $10.77.
Clinical Progress Continues: Kailera has completed enrollment in its Phase 3 ribupatide obesity trial, providing an important milestone despite the stock's weakness.
Investor Patience Tested: Significant private-market backing has not prevented selling pressure, while potential early-investor liquidity remains an overhang.


Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns